UBS Maintains a 'Buy' on Gilead Sciences (GILD); Raising PT on Lower Risk to HCV
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $147.60 --0%
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 9
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 9
Join SI Premium – FREE
UBS maintains a 'Buy' on Gilead Sciences (NASDAQ: GILD) price target raised from $53 to $61.
UBS analyst says, "GILD's disclosure on the 4Q call that all genotype 1 (GT1) HCV patients in the ongoing ELECTRON trial evaluable thus far have achieved a rapid virological response (RVR) in our view suggests lower risk to success in GT1 HCV. We fully acknowledge that RVR is far from predictive of eventual cures (SVR-12), but we reiterate that the RVR rate is consistent with the standout profile that GS-7977 has shown to date."
"We’ve lessened our risk adjustment to GS-7977 sales following RVR data: We’ve updated our model to reflect the quarter, and have made adjustments to our HCV forecasts. Specifically to HCV, we’ve lowered our risk adjustments to our GS-7977 HCV sales forecasts (from 15-30% to 5-25%, yielding peak sales in 2020 of $5.8bn), and have increased our HCV sales forecasts in our upside case scenario by 10% (upside case peak: $7bn)."
UBS lowers FY12 EPS estimate from $4.23 to $4.15 and FY13 from $4.82 to $4.77.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $54.70 yesterday.
UBS analyst says, "GILD's disclosure on the 4Q call that all genotype 1 (GT1) HCV patients in the ongoing ELECTRON trial evaluable thus far have achieved a rapid virological response (RVR) in our view suggests lower risk to success in GT1 HCV. We fully acknowledge that RVR is far from predictive of eventual cures (SVR-12), but we reiterate that the RVR rate is consistent with the standout profile that GS-7977 has shown to date."
"We’ve lessened our risk adjustment to GS-7977 sales following RVR data: We’ve updated our model to reflect the quarter, and have made adjustments to our HCV forecasts. Specifically to HCV, we’ve lowered our risk adjustments to our GS-7977 HCV sales forecasts (from 15-30% to 5-25%, yielding peak sales in 2020 of $5.8bn), and have increased our HCV sales forecasts in our upside case scenario by 10% (upside case peak: $7bn)."
UBS lowers FY12 EPS estimate from $4.23 to $4.15 and FY13 from $4.82 to $4.77.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $54.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi cuts Lowe's price target to $260, keeps Buy rating
- CIENA (CIEN) PT Lowered to $550 at BofA Securities
- Jefferies Starts Faraday Copper Corp (FDY:CN) (CPPKF) at Buy
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
